• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

pSivida seeks European regulatory nod for Durasert

June 22, 2017 By Sarah Faulkner

pSividapSivida (NSDQ:PSDV) is looking to market its Durasert 3-year treatment for posterior segment uveitis in the European Union. Today, the Watertown, Mass.-based company submitted a marketing authorization application to the European Medicines Agency.

Earlier this month, pSivida reported that its 2nd Phase III trial, which followed patients for 3 years, met its primary endpoint of prevention of recurrence of posterior uveitis at 6 months.

In the 153-patient trial, 21.8% of Durasert-treated patients had a recurrence compared to 53.8% of patients in the sham group.

The company also reported that intraocular pressure elevation was 2.4 mm Hg at 6 months for the Durasert group and 1.3 mm Hg for the sham group. Also, 41.6% of patients in the Durasert required IOP-lowering therapy at any time during the 1st 6 months follow-up and 34.6% for the sham group.

In patients with a natural lens at baseline, 4.9% in the group treated with Durasert needed a cataract surgery through 6 months versus 8.6% in the sham group.

“Our MAA submission is another significant milestone delivered on time by the pSivida team,” president &CEO Nancy Lurker said in prepared remarks. “Durasert 3-year uveitis treatment, our lead product candidate, has now proven to be highly effective in reducing the recurrence of uveitis in 2 Phase III studies.  Both studies illustrate the benefits Durasert brings to those patients suffering from this disease, which is a leading cause of blindness.  As we await the review from the EU regulators, we continue to have advanced discussions with potential partners and are focused on entering into an out-licensing agreement for Durasert in the EU sometime this summer.”

pSivida’s Durasert is an injectable, sustained-release drug delivery system that can last for up to 3 years. Administered in an office setting using a needle as small as 25-guage, the micro-insert is 3.5 millimeters in length with a diameter of 0.37 millimeters, according to the company.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: pSivida Corp.

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS